Investors include Soros Fund Management, Perceptive Life Science Fund
By Devika Patel
Knoxville, Tenn., Aug. 3 – Abeona Therapeutics Inc. said it completed an upsized $15.57 million direct placement of shares. The deal priced for $8.51 million on July 28.
The company sold 2.83 million common shares at $5.50 per share. The price per share is a 0.73% premium to the July 27 closing share price of $5.46.
Soros Fund Management and Perceptive Life Science Fund participated.
Proceeds will be used for development of the company’s rare disease programs, working capital and general corporate purposes.
Based in New York, Abeona develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases.
| Issuer: | Abeona Therapeutics Inc.
|
| Issue: | Common shares
|
| Amount: | $15,565,000
|
| Shares: | 2.83 million
|
| Price: | $5.50
|
| Warrants: | No
|
| Investors: | Soros Fund Management and Perceptive Life Science Fund
|
| Pricing date: | July 28
|
| Settlement date: | Aug. 3
|
| Stock symbol: | Nasdaq: ABEO
|
| Stock price: | $5.46 at close July 27
|
| Market capitalization: | $197.89 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
